November 25th, 2021

Allgenesis Biotherapeutics Inc., a Taiwan-based specialty pharmaceutical company focused on developing novel ophthalmic drugs, announced that it was granted a U.S. patent covering Allgenesis’ biologic product, AG-73305, a first-in-class drug that fuses a VEGF Trap and disintegrin into one molecule. The newly issued U.S. patent provides coverage of the fusion protein and its use to treat angiogenic diseases in the field of ophthalmology, such as AMD and DME, up to the year 2036.

AG-73305 already has patents granted in Australia, Europe, Japan, Korea, Mexico and Taiwan. We expect to seeing additional patent grants in China, Brazil, Canada, Singapore and India as we progress with our development plan,” said Dr. Madhu Cherukury, Chief Executive Officer of Allgenesis Biotherapeutics Inc.

The U.S. IND filing for AG-73305 and the subsequent first patient enrollment for the Phase 2a DME trial in the U.S. are expected in the first half of 2022. Allgenesis announced a licensing agreement (see press release here) in September 2021 with AffaMed Therapeutics for the development of AG-73305 in Greater China and having this patent granted in U.S. further strengthens our patent portfolio. For additional information and collaboration opportunities with Allgenesis, please send emails to info@allgenesis.com or jack.chang@allgenesis.com.

About Allgenesis Biotherapeutics Inc.

Allgenesis is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The company is focused on research and development of novel medicines for the treatment of eye diseases. Current projects in the pipeline include AG-73305, a potential blockbuster drug for the treatment of DME, nAMD, and other retinal diseases such as RVO, AG-86893 for pterygium, and AG-80308 for Dry Eye Disease.

About AG-73305

AG-73305 is a first-in-class molecule specifically designed for the treatment of DME, nAMD, and other retinal diseases such as RVO. AG-73305 is a single fusion protein that simultaneously binds with high potency and specificity to VEGF and integrin targets, which are known to be involved in retinal diseases. AG-73305 has the potential to treat anti-VEGF responders and non-responders.